METHOD FOR INDUCING MACROPHAGES, INDUCER FOR ANTI-INFLAMMATORY MACROPHAGES AND PHARMACEUTICAL COMPOSITION
|Posted date||Oct 30, 2020|
|International application number||2020JP009639|
|International publication number||WO2020184425|
|Date of international filing||Mar 6, 2020|
|Date of international publication||Sep 17, 2020|
|Title||METHOD FOR INDUCING MACROPHAGES, INDUCER FOR ANTI-INFLAMMATORY MACROPHAGES AND PHARMACEUTICAL COMPOSITION|
|Abstract||This method for inducing macrophages involves culturing macrophages in the presence of exosomes produced from interferon γ-added mesenchymal stem cells, and inducing anti-inflammatory macrophages. This inducer for anti-inflammatory macrophages contains exosomes produced from interferon γ-added mesenchymal stem cells as an effective ingredient. This pharmaceutical composition comprises said inducer.|
|Outline of related art and contending technology||
Mesenchymal stem cells (MSC) can be collected not only from bone marrow but also from medical wastes such as adipose tissue and umbilical cord tissue, have low antigenic properties, can also use other cells, and have various roles such as anti-inflammatory, antifibrosis, angiogenesis, antioxidation, and the like. However, it has been reported that MSC is slightly different depending on the cell type from which MSC is derived, and the properties of MSC are changed when they enter into culture conditions and living bodies, and the mechanism of the effect has not been clarified yet. MSC is expected to act on many immune cells through the production of cytokines, chemokines, growth factors, exosomes, and the like as "conducting cells", but the influence on macrophages is paid attention to the pathology of liver cirrhosis.
So far, the inventors have found that MSC changes the polarity of myeloid-derived cultured macrophages to), also referred to as anti-inflammatory macrophages ("M2 macrophages", thereby acting on fibrogenesis improvement and regeneration promotion during liver cirrhosis, for example, see) Non-Patent Document 1.
However, it is known that most of MSC are delivered to the lungs when administered intravenously and very few of MSC are delivered to the liver. Nevertheless, it is presumed that some MSC expression substance is involved in liver cirrhosis because of showing the above effect on liver cirrhosis, but the detailed mechanism of which substance changes the polarity of macrophages has not been clarified.
|Scope of claims||
|IPC(International Patent Classification)||
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Contact Information for " METHOD FOR INDUCING MACROPHAGES, INDUCER FOR ANTI-INFLAMMATORY MACROPHAGES AND PHARMACEUTICAL COMPOSITION "
- Niigata University (In Japanese)研究支援部産学連携課
- URL: https://www.niigata-u.ac.jp/
- Address: 8050,Ikarashi 2no-cho,Nishi-Ku,Niigata,Japan , 950-2181
- Phone: 81-25-262-7554
- Fax: 81-25-262-7513